share_log
Moomoo 24/7 ·  02/05 16:16

Exicure Shares Are Trading Higher After the Company Announced It Entered Into a Patent License Agreement With Bluejay Therapeutics to Develop Cavrotolimod for the Potential Treatment for Hepatitis

Exicure宣佈與Bluejay Therapeutics簽訂專利許可協議,開發用於潛在肝炎治療的卡夫羅託莫德後,該公司股價走高

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論